Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(9):629; doi:10.1093/jnci/97.9.629
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Travis, K.
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Travis, K.
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

Kate Travis, Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Clinical Trial of Vaccine Shows Reduction in HPV Infection Rates

A randomized phase II clinical study has found that a vaccine that targets four prevalent types of human papillomavirus (HPV) reduces persistent infection with the virus and diseases associated with it.

The vaccine targets HPV types 6 . . . [Full Text of this Article]

Half of Cancer Deaths Preventable, Society Reports


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?